Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Ramelteon

Nature Reviews Drug Discovery volume 4, pages 881–882 (2005)Cite this article

Abstract

Ramelteon (Rozerem; Takeda), a melatonin receptor agonist, was approved by the US FDA for the treatment of insomnia in July 2005. In contrast to other widely used drugs for this condition, it has shown no evidence of dependence or abuse potential, and has not been designated as a controlled substance.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Melatonin and ramelteon.

References

  1. Kupfer, D. J. & Reynolds, C. F. Management of insomnia. N. Engl. J. Med. 336, 341–346 (1997).

    Article  CAS  Google Scholar 

  2. Brzezinski, A. Melatonin in humans. N. Engl. J. Med. 336, 186–195 (1997).

    Article  CAS  Google Scholar 

  3. Turek, F. W. & Gillette, M. U. Melatonin, sleep and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med. 5, 523–532 (2004).

    Article  Google Scholar 

  4. Uchikawa, O. et al. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. J. Med. Chem. 45, 4222–4239 (2002).

    Article  CAS  Google Scholar 

  5. FDA labelling information [online], <http://www.fda.gov/cder/foi/label/2005/021782lbl.pdf> (2005).

  6. Brzezinski, A. et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med. Rev. 9, 41–50 (2005).

    Article  Google Scholar 

  7. IMS Health Analysis, IMS MIDAS Quantum, MAT (March 2005).

Download references

Author information

Authors and Affiliations

  1. University of Pittsburgh School of Medicine, Pennsylvania, 15213, USA

    Daniel Buysse

  2. IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK

    Guy Bate

  3. Nature Reviews Drug Discovery, UK

    Peter Kirkpatrick

Authors
  1. Daniel Buysse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guy Bate
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buysse, D., Bate, G. & Kirkpatrick, P. Ramelteon. Nat Rev Drug Discov 4, 881–882 (2005). https://doi.org/10.1038/nrd1881

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1881

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing